- Home
- MYGN vs PAR Comparison
MYGN vs PAR Comparison
Compare MYGN & PAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- PAR
- Stock Information
- Founded
- MYGN 1991
- PAR 1968
- Country
- MYGN United States
- PAR United States
- Employees
- MYGN N/A
- PAR N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- PAR Office Equipment/Supplies/Services
- Sector
- MYGN Health Care
- PAR Miscellaneous
- Exchange
- MYGN Nasdaq
- PAR Nasdaq
- Market Cap
- MYGN 744.7M
- PAR 2.8B
- IPO Year
- MYGN 1995
- PAR N/A
- Fundamental
- Price
- MYGN $5.30
- PAR $67.77
- Analyst Decision
- MYGN Hold
- PAR Strong Buy
- Analyst Count
- MYGN 15
- PAR 7
- Target Price
- MYGN $15.14
- PAR $79.86
- AVG Volume (30 Days)
- MYGN 1.9M
- PAR 403.6K
- Earning Date
- MYGN 08-05-2025
- PAR 08-07-2025
- Dividend Yield
- MYGN N/A
- PAR N/A
- EPS Growth
- MYGN N/A
- PAR N/A
- EPS
- MYGN N/A
- PAR N/A
- Revenue
- MYGN $831,300,000.00
- PAR $383,768,000.00
- Revenue This Year
- MYGN N/A
- PAR $30.06
- Revenue Next Year
- MYGN $6.68
- PAR $16.97
- P/E Ratio
- MYGN N/A
- PAR N/A
- Revenue Growth
- MYGN 7.38
- PAR 37.95
- 52 Week Low
- MYGN $3.81
- PAR $43.50
- 52 Week High
- MYGN $29.30
- PAR $82.24
- Technical
- Relative Strength Index (RSI)
- MYGN 55.01
- PAR 59.85
- Support Level
- MYGN $4.90
- PAR $62.65
- Resistance Level
- MYGN $5.29
- PAR $68.10
- Average True Range (ATR)
- MYGN 0.25
- PAR 1.88
- MACD
- MYGN 0.09
- PAR 0.23
- Stochastic Oscillator
- MYGN 93.44
- PAR 92.77
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About PAR PAR Technology Corporation
PAR Technology Corp is a foodservice technology company providing omnichannel cloud-based software and hardware solutions to the restaurant industry in three restaurant categories - quick service, fast casual, and table service - and the retail industry, including convenience and fuel retailers (C-Stores). The company's product and service offerings include point-of-sale, customer engagement and loyalty, digital ordering and delivery, operational intelligence, payment processing, hardware, and related technologies, solutions, and services. The company generates revenue from subscription service, Sale of Hardware products, and Professional Service.